News

BRW this week announced the 10 best start-ups for 2011, and OneVentures investment Vaxxas was amongst the 10...

Smart Sparrow has set out to revolutionise e-learning in Australia

Consider Vaxxas, a company that received funding from an IIF fund manager, OneVentures, last year. Vaxxas is developing a way to deliver vaccinations via a patch rather than needle and syringe. For most of us, a patch is a helluva lot nicer than a jab but for millions of people in developing countries, Vaxxas may be life-saving.

Brisbane technology developer Peak3 has secured over $2.3m in public and private funding to commercialise its diesel particulate emissions management systems. These are based on acoustic filtration technology for reducing ultra-fine particles and include emissions monitoring systems.

OneVentures Innovation Fund has invested in first clean technology to support Peak3, a company based in Brisbane, to commercialize services and products for the treatment, management, and monitoring of particular emissions in diesel engine.

DeOvo™ demonstrates safety and clear efficacy against head lice and their eggs from one single application and is now positioned to accelerate into Phase 3.

Sydney, December 16, 2011 – Smart Sparrow Pty Ltd, have today announced it has secured a significant round of venture capital investment to accelerate the commercialisation of its proprietary online Intelligent Tutoring e-learning platform.

A PLAN to deliver vaccines to millions of the world's poor through biomedical patches the size of postage stamps was named the overall winner at The Australian Innovation Challenge awards in Brisbane.

“Hatchtech Pty Ltd is pleased to announce the appointment of Mr. Timothy Waugh as Chief Executive Officer.”

“Barminco plans to develop a diesel particulate management plan.”

The state has also injected another $3 million into supporting digital content projects.

Tears in the doctor's surgery at immunisation time could be a thing of the past thanks to the development of a needle-free vaccination that can be mailed to your home.

MELBOURNE, Victoria: Pharmaceutical company Hatchtech Pty Ltd has completed treatment of subjects for its Phase 2b clinical study to confirm the efficacy of its novel head lice treatment DeOvo™.

Getting your shots at the doctor could be a pain-free experience thanks to the commercialisation of a needle-free vaccination called NanopatchTM – made possible by the Australian Government’s Innovation Investment Fund.